Angiotensin-converting enzyme (ACE) inhibitors are commonly prescribed to manage hypertension and heart failure. Inhibition of ACE decreases the formation of the vasoconstrictor angiotensin II and reduces the metabolism of the vasodilator bradykinin, thereby contributing to lower blood pressure [1] . In 2015, 7% of the Swedish population was prescribed an ACE inhibitor [2] . Although ACE inhibitors are considered relatively safe, a substantial number of patients (5-35%) experience an adverse drug reaction (ADR) in the form of persistent dry cough that may lead to treatment discontinuation. Cough symptoms generally disappear within a month of drug withdrawal, but may remain longer in some patients [3] . Female sex, chronic obstructive pulmonary disease (COPD) and asthma are possible risk factors for ACE inhibitor-induced cough [4] . The effect of cigarette smoke is debated, as an increased risk of drug-induced cough has been reported for both smokers [4, 5] and nonsmokers [6] . Patients experiencing ACE inhibitor-induced cough are generally changed to an angiotensin receptor blocker, which is less associated with this type of ADR [7] .
The pathogenesis of ACE inhibitor-induced cough is believed to be associated with increased plasma levels of bradykinin, substance P and prostaglandins [6, 8] . Candidate gene studies of these pathways have identified suspected causative SNPs in certain patients. The candidate genes include BDKRB2 [9] [10] [11] [12] , MME [12] , PTGER3 [12] , NK2R (TACR2) [13] and ACE [11, 12] . One study also reported an association with the blood group factor gene ABO [11] . Overall,results from these candidate genes have been inconsistent across studies. A recent genome-wide association study (GWAS) in patients with ACE inhibitor-induced cough performed in a mixed ancestry American population [14] further identified associations with SNPs in the potassium channel gene KCNIP4. The strongest associations with KCNIP4 were in patients of European ancestry. We performed a GWAS on ACE inhibitor-induced cough in a genetically homogenous Swedish Genetic variants associated with angiotensin-converting enzyme inhibitor-induced cough: a genome-wide association study in a Swedish population future science group Research Article Hallberg, Persson, Axelsson et al. population, and used our dataset to replicate candidate genes identified in previous studies.
Patients & methods

Sample description
Cases were recruited through SWEDEGENE [15] , which is a biobank of ADRs run by Uppsala University in collaboration with the Swedish Medical Products Agency and Karolinska Institutet in Sweden. The majority of the cases were recruited from spontaneous ADR reports sent from healthcare professionals to the national drug regulatory authority. Clinical data (demographics, medical history, drug treatment history, laboratory data and ancestry) were collected through interviews using a standardized questionnaire, and by obtaining and reviewing medical records. All potential cases were evaluated by an investigator to ensure time relationship with an ACE inhibitor, and a positive dechallenge within 3 months following treatment discontinuation [16] . This resulted in 124 included cases, where the drug was plausably causative of cough symptoms. DNA was extracted from peripheral venous blood. Cases were genotyped using the Illumina HumanOmni2.5 array.
Treated controls were available from the Swedish Twin registry [17] . Twins who had collected at least two prescriptions of ACE inhibitors between 2005 and 2012 based on data from the National Prescribed Drug Register [2] were eligible. Only one twin from each pair was selected, resulting in a total of 1345 unrelated controls. A majority of the controls were of Swedish origin. Disease history was obtained from a subset of the treated controls (n = 956). The International Classification of Diseases (ICD) diagnoses included in the study were hypertension (ICD-10: I10-I15), heart failure (ICD-10: I50), diabetes (ICD-10: E10-E14), COPD (ICD-10: J43), emphysema (ICD-10: J44) and asthma (ICD-10: J45). The controls had previously been genotyped using the Illumina HumanOmniExpress 700K BeadChip ( Illumina, CA, USA).
Power calculation
When using all 124 cases and 1345 controls, the power to detect an odds ratio (OR) between 2 and 4 was 80% for variants with minor allele frequencies (MAFs) between 10 and 50% (Supplementary Figure 1) . The calculation was based on a genome-wide significance level of p < 5 × 10 -8 , an ADR prevalence of 10% and an additive genetic model [18] .
Genome-wide array data & analyses
We performed GWAS on 124 patients with ACE inhibitor-induced cough and 1345 treated controls. Cases were genotyped on an array that contained more SNPs than that used for the controls. Only 596,010 SNPs that were available on both arrays after quality control were utilized in the imputation. The 1.9 million discarded SNPs were used to check imputation quality by comparing imputed SNPs with directly typed SNPs in the cases, when available.
Phasing and imputation were performed using the Michigan Imputation Server with the Eagle and Minimac3 pipeline and the Haplotype Reference Consortium panel as reference [19] [20] [21] . Post imputation, variants with Minimac3 R-squared value <0.3 were filtered out, and the data were converted to hardcall PLINK format using PLINK with QC criteria of 0.5% MAF, maximum 5% missing per individual and maximum 10% missing per SNP. The final dataset contained 8.6 million SNPs. In order to account for possible population stratification, principal component analysis (PCA) was performed on the nonimputed data (Supplementary Figure 2) . Four genetic outliers were detected using PCA, and half of them were cases ( Supplementary Figures 2 & 3) . The outliers were not excluded from the data.
All genome-wide analyses were adjusted for sex and the first four genetic principal components from the PCA. SNP effects were modeled as additive. The conventional genome-wide significance threshold p < 5 × 10 -8 was used to correct for multiple testing [22] . Genome-wide analyses were performed using PLINK v1.9 and individual SNP analyses were performed using R 3.2.2 (R Foundation for Statistical Computing, Vienna, Austria).
Candidate gene analysis
Our dataset was used to replicate selected genes that had previously been associated with a risk to develop cough from ACE inhibitors (Table 1) . In total 11,510 variants were available from or within 10 kb of the candidate genes. The significance threshold for the candidate genes was set to the Bonferroni limit of 0.05/11,510 = 4.3 × 10 -6 . 
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Results
Baseline characteristics & outcomes
Baseline characteristics for cases and controls are shown in Tables 2 & 3, respectively. There was a larger percentage of females than males among cases (61 vs 39%). A majority of the cases had Swedish origin (87.9%). Among the cases with origins outside of Sweden, eight had ancestry from another Nordic country, four from Sweden plus another Nordic country, two from another European country and one from the Middle East. The most common ACE inhibitor used by cases was enalapril (87.9%). A majority of the cases (91.1%) had a disease history of hypertension, whereas 13.7, 8.9, 4.0 and 0.2% had been diagnosed with diabetes, asthma, COPD/emphysema and heart failure, respectively. In addition, 12.9, 14.5, 24.2 and 34.7% of the cases had taken medications for obstructive airway diseases, calcium channel blockers, diuretics and beta blockers within 3 months before the reported ADR.
There were more males than females in the treated control group (64 vs 36%). Among the controls with known disease history (n = 956), 69.9% were diagnosed with hypertension, 24.1% with diabetes, 16.9% with heart failure, 5.8% with COPD/emphysema and 3.2% with asthma. Due to lack of disease history from a subset of controls, diagnoses were not compared between cases and controls. The most commonly used ACE inhibitors among controls were enalapril (78.4%) and ramipril (17.8%).
Genome-wide association analyses
Overall, there was high concordance between MAFs for imputed SNPs and directly typed SNPs in the cases (Supplementary 
Functional annotation of top hits
Study of the genomic background for the top 60 GWAS SNPs revealed that the vast majority (58/60) was located in intronic or non-coding intergenic regions. The two SNPs reported in coding sequences were rs61733199, a missense mutation in the GYS2 gene, and rs61753726, a synonymous substitution in the VPS13B gene (Supplementary Tables 2 & 3) . Functional annotations were obtained intersecting the top GWAS SNPs with chromatin state models based on imputed data from the Roadmap Epigenome Project [25] . We used annotations in 15 brain-and five lungderived tissues that were likely to be suitable models for the study of cough (Supplementary Tables 4-6 ). All CLASP1 SNPs except rs62151111 were located in intronic or intergenic regions. According to the ENCODE project, rs62151111 is located in a regulatory element in the 3´-UTR of CLASP1 with evidence of several transcription factors binding [26] . SNPs in TGFA, SLC38A6 and MMP16 were located in introns, and TGFA SNPs had evidence of enhancer activity in brain and lung cells. In addition, the intronic PDE11A SNP rs11695211 was located in enhancer regions in lung fibroblasts and a lung carcinoma cell line. For more detailed information regarding the functional annotation analysis, see Supplementary Tables 4-6.
Candidate gene association analyses
None of the candidate genes associated with ACE inhibitor-induced cough in other studies (Table 1) , was significantly associated with cough in our dataset (Figure 3) . A detailed list of the top 60 results from the candidate gene analysis is found in Supplementary Table 7 . This includes SNPs in the potassium channel gene KCNIP4 identified by Mosley and colleagues [14] , although their top hit rs6838116 was not present in our dataset (Table 6 & Figure 4 ). KCNIP4 isoforms are predominantly expressed in neuro nal structures, and a connection between cough and neuronal activity was supported by our GWAS, although not statistically significant. Associations suggesting this were with rs115510347 in the calcium-activated potassium channel gene KCNMB2 Table 2 ).
Discussion
The mechanism of ACE inhibitor-induced cough remains unresolved, but has been suspected to involve bradykinin [3] . Polymorphisms in the candidate gene BDKRB2 have been associated with ACE inhibitorinduced cough in some [9] [10] [11] [12] , but not in other studies [27] [28] [29] . In the present GWAS, we identified a series of genes that could be of importance for cough mechanisms independent of the bradykinin pathway. Based on our results, variations in CLASP1, TGFA and MMP16 were tentatively associated with an increased cough risk (highest ORs 3.97, 8.73 and 10.07, respectively; Table 4 ), whereas SNPs detected in PDE11A protected against cough (OR: 0.44, Table 4 ). CLASP1, MMP16, TGFA and PDE11A are all expressed in a variety of tissues, including bronchial epithelial cells and lungs [30] .
CLASP1 encodes a protein that functions as a microtubule stabilizer [31] . Microtubules are important for orga n izing cell structures and are involved in many cellular processes, including cell division, cell migration and intracellular transport. In the respiratory tract, microtubules stabilize and coordinate the movement of microvilli in the respiratory epithelium, which is important for transporting mucus toward the pharynx. Absent or dysfunctional microvilli impair the clearance of mucus, which may trigger cough. Noscapine is an opium alkaloid without analgesic and euphoric effects that has been used as an antitussive agent to treat dry cough since the 1930s [32] . It acts as a bradykinin antagonist, but has also been shown to bind and inhibit microtubule dynamics [33, 34] . In a study performed in patients with ACE inhibitor-induced cough, it was observed that noscapine relieved cough in 90% of the patients within 4-9 days [35] . This suggests that noscapine could have effects on both bradykinin and microtubule systems, offering the intriguing hypothesis that noscapine has a bradykinin-independent antitussive effect on ACE inhibitor-induced cough. The most significantly associated SNPs in Mosley et al [14] . The SNP rs6838116 is not presented, since it was not available in our dataset. † These SNPs were in complete linkage disequilibrium. OR: Odds ratio. 
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TGFA is an endogenous ligand for EGFR, whose signaling pathway has been associated with regulation of mucin production in airways [23, 36] . Mucins are gel-forming glycoproteins and major components in mucus that upon airway accumulation trigger a neural reflexive cough.
MMPs are involved in cell proliferation and migration and have a variety of physiological functions, including angiogenesis and degradation of extracellular matrix (ECM). In total, there are more than 20 identified MMPs, classified based on mole cular structure or substrate specificity. MMP16 contains a transmembrane region, thereby belonging to a membranetype of MMP [37] . The primary ECM substrates for MMP16 are fibronectin and collagen type III [24, 30] . It was previously shown that MMP12 secretion in human bronchial tissue is upregulated by inflammatory mediators, suggesting an involvement in the pathological changes seen for a variety of respiratory disorders, including asthma and COPD [38] . In a more recent study, MMP1 was suggested to affect ECM in the respiratory tract [39] , as its expression was elevated in respiratory tissue from asthmatic patients compared with controls. The broad-spectrum MMP inhibitor marimastat was also observed to increase allergen tolerability in allergy-induced asthmatic patients [40] . Taken together, these studies all support an involvement of MMPs in respiratory function.
PDEs degrade intracellular cAMP to 5´AMP, which in turn decreases enzyme activity of PKA. In contrast, PDE inhibition leads to maintained cAMP levels and enhanced PKA activity, which is associated with Figure 4 . Region plot of KCNIP4. The green line and the red dot indicate rs1495509, which was significantly associated with angiotensin-converting enzyme inhibitor cough in Mosley et al. [14] . reduced bronchoconstriction, airway inflammation and emphysema [41] . As a consequence, a number of PDE inhibitors have been tested for treatment of respiratory disorders. For instance, the selective PDE4 inhibitor roflumilast was approved in 2010 to manage COPD, with an ability to reduce inflammation and improve forced expiratory volume [42, 43] . Low-dose papaverine, which is a combined PDE4 and PDE10 inhibitor, was also reported to reduce cough induced by enalapril in guinea pigs [44] . In a GWAS performed in children suffering from allergy-induced asthma, DeWan and colleagues further found association with genetic variation in PDE11A, although no findings were genome-wide significant after correction for multiple testing [45] . The SNP rs2573088 identified in that study is located close to rs2573083 and rs2573085 that were associated with cough in our study (Table 4) , which supports an association between PDE11A and respiratory disorders.
Female gender has previously been identified as a risk factor for ACE inhibitor-induced dry cough, and this was consistent with the gender distribution in our cases. None of the candidate genes identified in previous studies showed genome-wide significance when replicated in our dataset. Although genetic variations affecting the bradykinin pathway seem to explain the risk for ACE inhibitor-induced cough in some individuals, it cannot be used to predict cough risk in most patients. Therefore, our study clearly underlines the importance of replicating studies to ensure true positive associations between genetic variants and ADRs.
Limitations of the study
The study has some limitations that deserve attention. First, it was performed in a limited number of cases, which could have caused the lack of genome-wide significant hits, although we detected some SNPs that were close to the significance level. Second, as the ACE inhibitor dose is commonly titrated at treatment initiation it was not possible to obtain the exact dose at which the ADR occurred in individual patients. Third, treated controls were eligible for the study if they had received two or more prescriptions of ACE inhibitors, based on the assumption that patients returning to the pharmacy for a second prescription of the same medication are less likely to have experienced any significant negative effects. This might however have biased our study, as cough as an ADR is easily mistaken and underreported. In addition, the results obtained here have not yet been replicated and further studies are future science group GWAS of ACE inhibitor-induced cough Research Article needed to ensure their validity. A strength of the study is that the high imputation quality indicates that the results obtained from the GWAS are reliable. However, larger sample sizes are required to confirm the association between the novel genes found in our study and ACE inhibitor-induced cough.
Conclusion
In this GWAS, near significant associations between ACE inhibitor-induced cough and genes outside the bradykinin pathway were detected. A relationship with the potassium channel gene KCNIP4 was not confirmed, but there was a tentative association with another potassium channel gene, KCNMB2. Further, there were interesting associations with putative regulatory elements in the genes CLASP1, PDE11A and TGFA, all of which have been implicated in airway function. These novel findings may increase the understanding of mechanisms behind ACE inhibitor-induced cough.
Future perspective
Overall, the clinical benefit of genotyping variants that predict the risk of ADRs is estimated to be greater than that of genotyping variants that increase the risk of disease. The main reasons are that genetic variants associated with pharmacogenomic phenotypes in general have larger effect sizes than variants associated with complex disease risk, and it is easier to select an alternative drug for a patient than to modify his risk factors for complex disease [46] . Although the findings in our study do not merit predictive genotyping, future research will undoubtedly identify many other clinically actionable associations with drug response. It is anticipated that before long, patients will have their pharmacogenome available in the medical record at the time of drug prescription [47] . This would be vital for the prediction and prevention of serious and unnecessary adverse reactions, and be an important step toward precision medicine.
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Executive summary
Background
• Dry cough is the most common adverse drug reaction (ADR) of angiotensin-converting enzyme (ACE) inhibitors and affects 5-35% of the patients.
• Female sex and respiratory disorders (asthma and chronic obstructive pulmonary disease) are known risk factors.
• The mechanism behind ACE inhibitor cough has been suspected to involve genetic variations in the bradykinin pathway, for example in BDKRB2, MME, PTGER and NK2R.
Patients & methods
• A genome-wide association study was performed to identify SNP variations associated with ACE inhibitor-induced cough.
• A total of 124 cases and 1345 treated controls were included in the study and genotyped using Illumina arrays.
Results
• Nearly genome-wide significant SNPs were detected in noncoding regions of CLASP1, PDE11A, TGFA, MMP16, KCNMB2 and SLC38A6.
• The top hit was rs62151109 in CLASP1 (OR: 3.97 [95% CI: 2.39-6.59]; p = 9.44 × 10 -8 ).
• rs62151111 in CLASP1 was located in a regulatory element and rs11695211 in PDE11A in an enhancer region.
• None of the candidate genes was associated with cough in our dataset.
Discussion
• Variations in CLASP1, TGFA and MMP16 were associated with increased cough risk, whereas variations in PDE11A reduced the risk.
• CLASP1 and TGFA may be important for cilia movement and mucin production for adequate airway function and mutations in these genes could possibly trigger cough.
• Mutations in MMP and PDE genes have been implicated in respiratory airway disorders, such as asthma and chronic obstructive pulmonary disease.
• ACE inhibitor-induced cough might be partly explained by variation in genes other than those associated with the bradykinin pathway. No writing assistance was utilized in the production of this manuscript.
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